News | December 15, 2022
Briefs: Jubilant Pharmova and Apollo Hospitals Enterprise
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
With the receipt of the EIR, the inspection stands successfully closed.
he US FDA has issued six observations pursuant to the completion of the audit.
Post this currently only Risperidone orally disintegrating tablets are allowed for import into the US from the Roorkee facility.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
This agreement is in addition to the $92 million filling line expansion announced in November 2021
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
